66th ASH Annual Meeting: Understanding Immediate Toxicities of Current Gene and Cell Therapy Tools

Symposia: Scientific Workshop on Genomic Toxicities of Gene and Cell Therapies Scientific Workshops

Room 31 (San Diego Convention Center)

Moderators:

Marina Cavazzana, MD, PhD, ARRAY(0x10a5a454) and Saar Gill, MD, PhD, University of Pennsylvania

Disclosures:

Gill: Mission Bio: Membership on an entity's Board of Directors or advisory committees; Asher Biotherapeutics: Research Funding; Novartis: Patents & Royalties, Research Funding; Carisma: Current holder of stock options in a privately-held company; Interius: Current holder of stock options in a privately-held company, Research Funding.

This session will focus on the basic biology that enables gene editing and correction and a discussion of the clinical implications of these novel therapies.

Moderator Introduction (Classical Hematology Perspective)

Marina Cavazzana, MD, PhD

Assistance Publique-Hôpitaux de Paris, Paris, France; Imagine Institute, Paris, France

Moderator Introduction (Malignant Hematology Perspective)

Saar Gill, MD, PhD

University of Pennsylvania, Philadelphia, PA

Ex Vivo Genetic Modification and Hematopoietic Cell Transplantation

Annarita Miccio, PhD

Imagine Institute, Paris, France

Ex Vivo Genome Editing of Immune Cells

Marcela Maus, MD

Harvard Medical School, Lexington, MA

Hematopoietic Cell Transplantation Versus Gene Therapy for Hemoglobinopathies

Janet L. Kwiatkowski, MD

Children's Hospital of Philadelphia, Philadelphia, PA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Hematopoietic Cell Transplantation Versus Gene Therapy for Blood Cancers

Noelle Frey, MD, MS

University of Pennsylvania, Philadelphia, PA

Panel Discussion

See more of: Scientific Workshop on Genomic Toxicities of Gene and Cell Therapies
See more of: Scientific Workshops

<< Previous Session | Next Session >>